[Dental nerve response induced by pressure on the tooth of the cat].
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to M Funakoshi.
Explore the source record for details and available documents.
1. The relationship between physical fitness (maximal oxygen uptake VO2max) and incidence of hypertension was investigated through a prospective study for a total of 16,525 human-years of observation. 2. This study involved 3305 Japanese males whose blood pressure (BP) was normal when they received their first physical examination before the age of 50. They were monitored from 1983 to 1988. The BP of 425 subjects was diagnosed as hypertension in the fifth year. 3. Fitness levels were divided into quintiles according to VO2max levels, and were compared with the changes of BP and relative risk of hypertension after adjustment for age, initial percentage of body fat (PFAT), initial BP, alcohol consumption, cigarette smoking status and familial history of hypertension. The increase in BP of subjects in the least fit group was higher than in any other group. Relative risk was calculated using a multiple logistic regression and was 1.9 x higher in the least fit group compared with the fittest group. 4. The subjects were classified into three groups: the improved VO2max group, the deteriorated VO2max group and the unchanged VO2max group. The increase in BP of the improved VO2max group was significantly lower than the other two groups after adjustment for changes in PFAT, age, initial PFAT, initial BP, fitness level, alcohol consumption, cigarette smoking status and familial history of hypertension. 5. It is concluded that low VO2max level is related to higher incidence of hypertension. An improved VO2max would therefore be able to prevent hypertension.
The immunomodulatory effect of human immunosuppressive acidic protein (IAP) on lymphocyte surface antigens was investigated. IAP inhibited lymphocyte responses to phytohemagglutinin in a dose-dependent manner. By flow cytometry, using fluorescein-isothiocyanate-labelled antibodies, the mean fluorescence intensity on peripheral blood lymphocytes (PBLs) decreased for CD4, slightly decreased for CD3 but showed no change for the CD8 and T cell receptor alpha-beta antigens in the presence of IAP. This CD4 antigen modulation by IAP was observed in PBLs freshly isolated from patients with unresectable cancer but not in those isolated from patients with resectable tumor or from healthy volunteers. The modulation of the CD4 antigen by IAP on the lymphocyte surface was correlated with an increment of serum IAP levels in cancer patients. The CD4 modulation could be induced in PBLs from healthy volunteers by culturing them with IAP in vitro. It is suggested that IAP may play a role in cancer-related immunosuppression through the down-modulation of the CD4 antigen on the lymphocyte surface.
Explore the source record for details and available documents.
The jaw muscles responded to changes in the head position. Electromyographic responses to head positions were classified as either of two types--balanced and unbalanced. The balanced type of electromyographic responses of participants with normal occlusion changed to the unbalanced type after being set with an overlay to make a premature contact artificially, and returned to the balanced type after removal of the overlay. The unbalanced type of electromyographic response of participants with occlusal interference turned to the balanced type after occlusal adjustment.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
The mechanism of defective natural killer (NK) activity in gastric cancer patients was studied with respect to the soluble immune suppressor factor receptor on NK cells. Phycoerythrin (PE)-conjugated anti-CD8 and -CD16 antibodies were used for the determination of NK phenotype, and fluorescein isothiocyanate (FITC)-conjugated wheat germ agglutinin (WGA) was for the lymphocyte surface receptor of soluble immune suppressor factor (SISF). It was found that NK activity of peripheral blood lymphocytes (PBLs) isolated from gactric cancer patients decreased with tumor progression in spite of an increasing tendency of their CD16+ population. The WGA+ population of PBLs inversely increased in parallel with cancer progression and a significant negative correlation was found between NK activity and the WGA+ population. Two-color flow cytometry showed a significant increase of WGA+ cells in the CD8dim and CD16+ population in advanced cancer patients. It is suggested that an increase of surface receptors for SISF on NK cells may, in part, cause the diminished NK activity in gastric cancer patients.
The clinical efficacy of intraperitoneal administration of OK-432 plus interleukin-2 (IL-2) for treating malignant ascites was evaluated in gastric cancer patients. Ten KE of OK-432 and 200,000 Jurkat units of IL-2 were intraperitoneally administered in tandem in the order given on alternate days at paracentesis. Of the 22 evaluable patients, 18 (81%) developed complete or partial responses, showing a cytologic disappearance of cancer cells and decrease of ascites. More than 50% of the patients obtained positive responses within 2 weeks after the initial administration of the drugs. Improvements of performance status and clinical symptoms such as abdominal fullness, followed by restoration of oral food intake and prolongation of survival time were observed in responders treated with OK-432 plus IL-2. Flow cytometric analysis demonstrated a predominant increase of the CD3+CD4+ cells, especially of the CD4+CD45RA- subset in the peritoneal cavity of the responders. Cytotoxicity assay after negative selection of the CD4+ cells with the antibody and complement revealed that the CD4+ subset possessed cytotoxic activity against autologous tumor cells. The results suggest that intraperitoneal administration of OK-432 plus IL-2 may not be only a practical but also an effective protocol for treating malignant ascites in gastric cancer patients.